Novel drugs have been reported to be of particular interest in lymphomas such as anti-KIR enhancing NK-cell-mediated cytotoxicity [44], anti-PD1 targeting T-cells infiltrating tumor [45], anti-CD137 targeting immune cells, including NK cells [46]. This evidence concerns the gene TNFRSF9 and neoplasm.